A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy SubjectsCastration Resistant Prostate Cancer (CRPC)Relative BioavailabilityMDV3100
Interventions
DRUG

MDV3100

Oral

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY